Karyopharm Therapeutics | Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 1.75B 2025-06
Abbott USD 1.74B 23.39B 2025-09
Amgen USD 539M 1000K 2025-12
AstraZeneca USD 1.55B 1.16B 2025-09
BioCryst Pharmaceuticals USD 1.9M 3K 2023-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 946.83M 354.23M 2025-06
Enanta Pharmaceuticals USD 212K 1000 2023-12
GlaxoSmithKline GBP 4.08B 49.43M 2025-12
Incyte USD 196.13M 2.01M 2025-09
J&J USD 2.41B 584K 2025-09
Karyopharm Therapeutics USD 13K 0 2024-09
MacroGenics USD 63.26M 62.63M 2025-09
Merck USD 2.49B 15.79M 2025-09
Nektar Therapeutics USD 19K 0 2024-09
Novartis USD 1.94B 23.4M 2025-06
Novartis USD 1.92B 17.06M 2025-09
Pfizer USD 5.69B 1000K 2025-09
Regeneron Pharmaceuticals USD 105.3M 1.1M 2025-09
Roche Holding CHF 795.62M 699.54K 2025-12
Takeda JPY 1.58B 2K 2025-12
Tectonic Therapeutic USD 14.86M 111.83K 2024-12
TG Therapeutics USD 155.21M 2.81M 2025-09
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Xencor USD 71.34M 46K 2025-09


Karyopharm Therapeutics Capitale Ordinario - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.